The use of dydrogesterone in the complex treatment of patients with ovarian endometriomas

Objective. To analyze the efficacy of dydrogesterone as an anti-recurrence hormone therapy in patients who underwent surgery for ovarian endometriomas. Patients and methods. This prospective single-center cohort study included 50 patients with histologically verified diagnosis of external genital endometriosis and ovarian endometriomas. The age of patients ranged between 22 and 45 years. All patients underwent laparoscopic cystectomy. In the postoperative period, patients received dydrogesterone (Duphaston) at a dose of 20 mg/day from day 5 to day 25 of the menstrual cycle for 12 months. Results. According to ultrasound after 12 months, no recurrence of ovarian endometriomas was registered in any case. Pregnancy occurred in 9 patients among those who planned it. The volume of menstrual blood loss did not exceed normal values in all 50 patients during treatment. Treatment tolerance was satisfactory, no adverse reactions were observed. Conclusion. To minimize the risk of endometriosis recurrence, it is necessary to prescribe long-term (at least 12 months) postoperative hormone therapy. Dydrogesterone from the 5th to the 25th day of the menstrual cycle provides effective treatment for endometriosis with a favorable safety profile, maintaining ovulation and restoring hormonal balance. Key words: endometriosis, endometriomas, endometrioid cysts, anti-recurrence therapy, dydrogesterone